Pioneering TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases
Kupando raises €13 million in Series A funding round
27-Sep-2022 -
Kupando, a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, announces today the closing of its Series A funding round which raised €13 million.
The funds will be used to complete IND-enabling work and to ...
cancer
infectious diseases
oncology
+1